(Q38611707)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Drug repurposing in oncology--patient and health systems opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Vikas P Sukhatme

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Gauthier Bouche

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

20 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

732-742

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

A new initiative on precision medicine

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The anatomy of medical research: US and international comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Phenotypic screening in cancer drug discovery - past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Multicomponent therapeutics for networked systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Drug repositioning: identifying and developing new uses for existing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Drug discovery. Repurposing with a difference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Predictive methods in drug repurposing: gold mine or just a bigger haystack?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

New sources of drugs for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Predicting new molecular targets for known drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The Connectivity Map: a new tool for biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Computational repositioning and preclinical validation of pentamidine for renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Drug target identification using side-effect similarity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Successful applications of computer aided drug discovery: moving drugs from concept to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

In silico drug repositioning: what we need to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Rational design of indoleamine 2,3-dioxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Prediction of drug-target interactions and drug repositioning via network-based inference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Unfinished business: target-based drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Systematic discovery of multicomponent therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Propranolol for severe hemangiomas of infancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Drug repurposing in pediatrics and pediatric hematology oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The major role of clinicians in the discovery of off-label drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

A review of the history, properties, and use of the immunomodulatory compound lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Estimates of benefits and harms of prophylactic use of aspirin in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Aspirin use and risk of colorectal cancer according to BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Aspirin use and survival after diagnosis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin use and lung cancer risk in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin--mode of action and clinical implications for diabetes and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Unlocking the potential of retinoic acid in anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The bicyclam AMD3100 story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Exploiting the critical perioperative period to improve long-term cancer outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

The sympathetic nervous system induces a metastatic switch in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Security and maximal tolerated doses of fluvastatin in pediatric cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Discovery and exploitation of novel targets by approved drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Rare cancers are not so rare: the rare cancer burden in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Mining for therapeutic gold

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Has the time come for metronomics in low-income and middle-income countries?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Metformin in breast cancer: time for action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

More multiarm randomised trials of superiority are needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Use of crowdsourcing for cancer clinical trial development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Comparative Effectiveness Questions in Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Antitumour immunity gets a boost

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Drug development costs jump to $2.6 billion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Intratumor heterogeneity: seeing the wood for the trees.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Daily aspirin use and cancer mortality in a large US cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

31 March 2020

Nonprofit drug companies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.169

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

31 March 2020

1 reference

12 December 2020

In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats.

1 reference

12 December 2020

Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival

1 reference

12 December 2020

Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma

1 reference

12 December 2020

The Repurposing Drugs in Oncology (ReDO) Project.

1 reference

12 December 2020

Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations.

1 reference

12 December 2020

The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells

1 reference

12 December 2020

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

1 reference

12 December 2020

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent

1 reference

12 December 2020

Primary extraosseous Ewing sarcoma of the lung in children

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.3332/ECANCER.2013.312

Identifiers

DOI

10.1038/NRCLINONC.2015.169

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483297%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference